Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Ev.FV in Epidermolysis Bullosa
NCT07230223Phase 2Recruiting
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus + fulvestrant in dystrophic epidermolysis bullosa (DEB). Started Jan 2024; status: recruiting.
02
Drugs
everolimus + fulvestrant
03
Conditions
dystrophic epidermolysis bullosa (DEB)
Beyond the preview
Go deeper on NCT07230223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07230223.